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This study aims to test the feasibility of a randomised clinical trial to evaluate how acupuncture affects atopic dermatitis (AD)
symptoms and quality of life and to explore potential biomarkers that may be associated with AD. It is a sham-controlled trial in
which 30 eligible patients will be randomly allocated in a 1 : 1 : 1 ratio to one of three groups: verum acupuncture (VA) group 1 (3
times weekly for 4 weeks); VA group 2 (twice weekly for 4 weeks); or sham acupuncture group (SA; twice weekly for 4 weeks). SA
will consist of nonpenetrating acupuncture. Outcome measures will include the Visual Analogue Scale for itch, SCORing Atopic
Dermatitis, and Eczema Area and Severity Index to evaluate AD symptoms improvement along with the Patient Oriented Eczema
Measure and Dermatology Life Quality Index to assess quality of life. Measures will be collected at baseline, once weekly during
the treatment period, and after a 4-week follow-up period. Blood collection will be at baseline and 4 and 8 weeks after treatment
and compared with healthy controls. Illumina sequencing will be used to profile microRNA expression in each group to explore
candidate microRNA biomarkers for specific effects of acupuncture in patients with AD. This trial is registered via US National
Institutes of Health Clinical Trials registry (ClinicalTrials.gov) on 15 July 2016, identifier: NCT02844452.
1. Background
The prevalence of atopic dermatitis (AD), a chronic relapsing
inflammatory skin disease characterized by eczematous and
intensely pruritic skin lesions [1, 2], is increasing worldwide
[3, 4]. In South Korea, about 13% of children and 3% of
adults were reported to be diagnosed with AD in a 2008–2011
survey [5, 6]. Pruritus associated with AD often induces
sleeping problems and patients with AD frequently complain
of a lowered health-related quality of life; for example, daily
activities and/or personal relationships may be restricted [7].
First-line therapy of AD is based on the use of emol-
lients and other systemic and/or topical treatments: topical
corticosteroid (TCS) and calcineurin inhibitors are recom-
mended as topical management; antimicrobials, systemic
immune-modulators, allergen-specific immunotherapy, and
phototherapy are used for systemic management [8–11].
However, other complementary and alternative therapies are
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commonly used by many patients with AD when conven-
tional treatments yield unsatisfactory relief or produce side
effects [12].
In Korea, patients with AD have frequently used Tra-
ditional Korean Medicine, such as acupuncture and herbal
medicine, for symptom management [13]; however, there
have been only a small number of clinical studies of AD
treatment with acupuncture and herbal medicine and even
fewer studies investigating the therapeutic effect of acupunc-
ture alone [12, 14]. This may explain why a recent system-
atic review failed to include any randomised clinical trials
(RCTs) of acupuncture as treatment of AD [15]. Neverthe-
less, previous reports have demonstrated that acupuncture
exerts an antipruritic effect on pruritogen-induced scratching
behaviour in an animal model and on allergen-induced
itch in patients with AD [16–19]. Considering its potential
antipruritic effect, this highlights the need for rigorously
designed and conducted trials in acupuncture field [15].
To overcome some weaknesses of previous studies and to
determinewhether acupuncture helpsAD symptommanage-
ment, we will conduct a randomised, sham-controlled feasi-
bility trial comparing two different doses of active acupunc-
ture treatment with a sham acupuncture control. We aim to
establish the feasibility of recruitment and to determine key
features, including optimal acupuncture treatment dose and
outcome measures, to inform a large-scale RCT in patients
with AD. Additionally, we will explore novel biomarker can-
didates that may be associated with the antipruritic effect of
acupuncture.
2. Materials and Methods
2.1. Objectives. The aims of this study are (1) to investigate
the feasibility of a large-scale randomised clinical trial to test
the antipruritic effect of acupuncture treatment compared
with a sham acupuncture in patients with AD; (2) to identify
the optimal dose and schedule of acupuncture treatment
and to identify outcome measures that will reflect symptoms
changes; and (3) to discover biomarkers that may be associ-
ated with the therapeutic effects of acupuncture.
2.2. Hypotheses
(1) Acupuncture treatment will mitigate pruritus and
other symptoms of AD and will improve quality
of life in patients with AD, compared with sham
acupuncture.
(2) Three times weekly acupuncture treatment over one
month will produce better outcomes than twice
weekly acupuncture treatment over one month.
(3) Certain biomarker levels might be affected by the
therapeutic effect of acupuncture and/or develop-
ment of AD.
2.3. Trial Design. A randomised, sham-controlled feasibility
trial will be conducted at the Kyung Hee University Korean
Medicine Hospital from June 2016 to April 2017 (Figure 1(a)).
In addition to patients with AD, healthy volunteers will be
recruited to compare various biomarkers between the groups
(Figure 1(b)).
2.4. Participants and Recruitment
2.4.1. Patients with AD
(1) Inclusion Criteria. Participants who meet all of the follow-
ing criteria will be included:
(1) Age 19 and older
(2) Meeting the Hanifin and Rajka criteria [20], with AD
symptoms appearing constantly for at least 3 months
prior to study enrolment
(3) Score > 3 points and <8 points on itch Visual Ana-
logue Scale (VAS): 1–10 scale
(4) SCORing Atopic Dermatitis (SCORAD) index score
10–40
(5) Not taking prescription drugs for AD for at least 1
month prior to enrolment
(6) Ability to understand the study protocol and to
voluntarily agree to participate
(7) Not participating in any other research studies for AD
for at least 1 month prior to enrolment.
(2) Exclusion Criteria. Participants who meet any of the
following criteria will be excluded:
(1) Severely fluctuating AD symptoms
(2) Treatments that are not allowed in this study, for
example, oral corticosteroids, which may affect the
study outcomes
(3) Asthma or bronchitis
(4) Other disorders that may affect the outcomes, for
example, anxiety or depression.
2.4.2. Healthy Controls
(1) Inclusion Criteria. Participants who meet all of the follow-
ing criteria will be included:
(1) Age 19 and older
(2) No present or past history of allergic diseases such as
AD, asthma, or allergic rhinitis
(3) Ability to understand the study protocol and to
voluntarily agree to participate.
(2) Exclusion Criteria. Participants who meet any of the
following will be excluded:
(1) Pregnant or lactating women
(2) History of anaphylaxis, severe hypertension, hypoten-
sion, or respiratory disease
(3) Regular use of antihistamines or steroids during the
previous month.
2.5. Recruitment. Advertisements will be posted on notice
boards of the hospital and local community centres.
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Figure 1:Flow of the trial. (a) Randomisation schema for participantswithAD. (b)Recruitment of healthy controls for comparativemicroRNA
expression profiling analysis against AD patients. AD, atopic dermatitis; CES-D, Centre for Epidemiologic Studies-Depression Scale; Cold-
Heat, questionnaire of cold-heat pattern identification based on diagnosis in Traditional Korean Medicine; DLQI, Dermatology Life Quality
Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented EczemaMeasure; PPT, Pressure PainThreshold; SCORAD, SCORing
Atopic Dermatitis; STAXI, state-trait anger expression inventory; VAS, Visual Analogue Scale.
2.6. Randomisation and Allocation Concealment. After sign-
ing the written consent, participants will undergo a screening
test to confirm eligibility. The baseline characteristics includ-
ing demographics, physical examination, medical history,
and severity of AD signs will be used to screen the eligible
participants according to the inclusion and exclusion criteria.
IndividualswithADwill be randomly assigned to one of three
groups via block randomisation. Healthy volunteers will not
be assigned to a treatment group (Figure 1).
An independent statistician will produce random num-
bers with the PROC PLAN of SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA) and transfer them to the Acupuncture and
Meridian Science Research Centre (AMSRC) at Kyung Hee
University, where each random number will be sealed in a
sequentially numbered opaque envelope by a staff member
who is otherwise not involved in this study.
At the beginning of the randomisation process, the
investigator will call the independent staff in the AMSRC to
receive the screening number of the participant. Then the
AMSRC staff screening ID and treatment assignment will be
documented in the trial master file.
2.7. Blinding and Code Breaking. Participants and the out-
come assessor will be blinded to the treatment allocation in
this trial. Since it is impossible to blind the Korean Medicine
Doctors (KMDs) who will give acupuncture treatments, they
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will be excluded from performing the outcome measure-
ments or analysing data. To ensure participant blinding, an
eye patch will be applied to patients during the acupuncture
treatment, and they will be unable to see the practice pro-
cedures. All the acupuncture treatments, regardless of group
assignment, will utilise the Park sham device (AcuPrime Co.,
Ltd., Exeter, UK), which is applied at the acupoints to block
participants from seeing whether or not the acupuncture
needles penetrate the skin [21]. The acupuncture needles and
device will be maintained in place for 15min in all treatment
groups. If a participant has a serious adverse event and
immediate cessation of acupuncture treatment is required,
the blinding code will be broken.
2.8. Interventions
2.8.1. Acupuncture Treatment. The acupuncture treatments
were based on the revised STandards for Reporting Inter-
ventions in Clinical Trials of Acupuncture (STRICTA) 2010
recommendations (Table 1) [22]. Both manual acupuncture
and intradermal acupuncture treatment will be given. The
acupuncture protocols reflect everyday clinical practice in
Korean Medicine.
In this study, manual acupuncture treatment is composed
of fixed acupuncture treatment and additional acupuncture
treatment: partially individualised acupuncture treatment
will be performed on the basis of the traditional meridian
theory and consensus by experts in acupuncture and AD.
The number of applied acupoints per patient per session
ranges from 6 to 19: 6 basic points and 10 optional points
(3 optional points can be applied bilaterally). All participants
with AD will receive acupuncture needling at 6 fixed points:
LI11, ST36, and PC6, bilaterally. The optional points include
ST43, GB41, LI2, TE3, SI3, TE6, SI2, BL66, LR3, and SP3.
The optional acupoints will be added in accordance with
individual signs or symptoms, contralaterally to the applied
signs or symptoms: ST43 and GB41 for gastric stuffiness
or dyspepsia; LI2 and GB41 for tenderness around ST25,
diarrhoea, or constipation; TE3 and SI3 for fullness in the
chest and hypochondrium; TE3 andTE6 for lower abdominal
pain plus tenderness on the chest centre; SI3 and GB41 or SI2
and BL66 for lower abdominal pain, dry skin, or heat in the
upper body and cold in the lower body; and LR3 and SP3 for
pain in hypogastric region with darkness of the sublingual
collateral vessels. A study coordinator will ask participants
about symptoms that might require additional acupuncture
treatment to reduce the bias. Regardless of group assignment,
all manual acupuncture treatment will be performed using
Park sham devices to maintain participant blinding. The
acupuncture treatment will be donewith disposable sterilised
stainless needles (40mm length and 0.25mm diameter;
DongbangAcupuncture Inc., Bundang, Seongnam,Korea) or
Park sham acupuncture needles (AcuPrime Co., Ltd., Exeter,
UK) according to the assigned groups. Manipulation tech-
nique will be performed to elicit “de qi” sensation.The needle
will be inserted up to 5 to 30mmdepending on acupoints and
retained for 15 minutes.
After removal of needles, intradermal needles using
1.5mm press tack needles (Haeng Lim SeoWonMedical Co.,
Korea) will be given to three acupoints per participant per
session: LI11 bilaterally and auricular-Shenmen contralater-
ally.This is aimed at mitigating AD-related pruritus with LI11
and reducing anxiety level with auricular-Shenmen [16, 23,
24]. Participants will be instructed by study staff to press the
applied press tack needles located on LI11 for 3 minutes when
they feel severe pruritus.
All acupuncture treatments will be carried out by the
same KMD, who was trained for 10 hours to guarantee that
he could perform the acupuncture treatments identically
according to the predefined protocol.
2.8.2. Verum Acupuncture Group 1 (VA1). Participants
assigned to the VA1 will receive 12 acupuncture sessions over
4 weeks, that is, 3 days/week. A telephone interview will take
place two weeks after the end of treatment to collect data on
the severity of pruritus symptoms, amount of TCS used, and
adverse effects. Participants’ final visit will occur 4 weeks
after the end of treatment. No other intervention will be
permitted during the study period.
2.8.3. Verum Acupuncture Group 2 (VA2). Participants
assigned to the VA2 will receive 8 acupuncture sessions over
4 weeks, that is, 2 days/week. A telephone interview will be
given two weeks after the end of treatment to collect data on
the severity of pruritus symptoms, amount of TCS used, and
adverse effects. Participants’ final visit will occur 4weeks after
the end of treatment. No other intervention will be permitted
during the study period.
2.8.4. Sham Acupuncture Group (SA). Participants assigned
to the SA group will receive 8 acupuncture sessions over
4 weeks, that is, 2 days/week. Sham acupuncture treatment
will be conducted on 6 control points: a point 1 to 2 cm
proximal and 1 cm medial to LI7, a point 1 cm proximal and
1 cmmedial to LI11, and a point 1 cm proximal and 1 cm lateral
to ST36, each bilaterally. Instead of intradermal needles,
the same sized stainless steel rings without needles, that is,
nonpenetrating intradermal needles, which were designed
and validated for blinding for our study, will be attached to
three control points: a point 1 cm proximal and 1 cm medial
to LI11, bilaterally, and finger point in the ear, contralaterally
[25]. Unlike VA1 and VA2, fixed acupuncture treatments
will be given, but questions about symptoms, TCS, and
adverse effects will be asked to participants in this group. A
telephone interview will also be given two weeks after the
end of treatment to collect data on the severity of pruritus
symptoms, amount of TCS used, and adverse effects. After the
4-week treatment period, participants will return for a final
visit at 4weeks after the end of treatment, identical toVA1 and
VA2.
2.9. Compliance and Discontinuation. During the study
period, each patient will receive either 12 or 8 treatment
sessions according to their group assignment. Since frequent
hospital visits may be the burden to participants and may
induce them to withdraw from the trial, we identified a
minimum number of treatments to be considered compliant,
as follows: at least 10 sessions of 12 should be completed for
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Table 1: Acupuncture treatment details based on the STRICTA 2010 checklist.
Item Detail
(1) Acupuncture rationale
(1a) Style of acupuncture
(i) MA and IA using PTN based on traditional meridian theory
(1b) Reasoning for treatment provided, based on historical context, literature sources, and/or
consensus methods, with references where appropriate
(i) Partially individualised MA treatments and IA treatments based on the traditional meridian
theory, clinical experience, and consensus by the experts in acupuncture and AD
(1c) Extent to which treatment was varied
MA: Partially individualised, that is, fixed points plus optional points according to symptoms
IA: Fixed treatment
(2) Details of needling
(2a) Number of needle insertions per subject per session (mean and range where relevant)
MA: From 6 to 19 body acupoints per participant per session
IA: 2 body acupoints and 1 auricular acupoint per participant per session
(2b) Names (or location if no standard name) of points used (uni/bilateral)
MA:
(i) Fixed points: PC6, LI11, ST36 bilaterally
(ii) Optional points: ST43, GB41, LI2, TE3, TE6, SI2, SI3, BL66, LR3, SP3 contralaterally (GB41,
TE3, SI3 can be applied bilaterally according to the signs or symptoms of the patient)
IA: LI11 bilaterally and auricular shenmen contralaterally
(2c) Depth of insertion, based on a specified unit of measurement or on a particular tissue level
MA: From 5 to 30mm, perpendicular to skin surface
IA: 1.5mm, perpendicular to skin surface
(2d) Response sought (e.g., de qi or muscle twitch response)
MA: “de qi” sensation
IA: None
(2e) Needle stimulation (e.g., manual, electrical)
MA: Manual stimulation, needle rotation with thumb and index fingers for the first 10–15
seconds
IA: Participants will be educated to press PTNs for 3 seconds when they feel severe itch
(2f) Needle retention time
MA: 15 minutes
IA: 1-2 days or until PTN falls off
(2g) Needle type (diameter, length, and manufacturer or material)
MA: A sterilised stainless steel needle (0.25 × 40mm, Dongbang Acupuncture Inc., Bundang,
Seongnam, Korea)
IA: A hypoallergenic PTN (1.5mm, 10 × 10mm adhesive tape, Haeng Lim Seo Won Medical
Co., Korea)
(3) Treatment regimen
(3a) Number of treatment sessions
(i) 8 or 12 sessions according to the allocated group
(3b) Frequency and duration of treatment sessions
(i) Twice or 3 times a week for 4 weeks, 20 minutes for each session
(4) Other components of treatment
(4a) Details of other interventions administered to the acupuncture group (e.g., moxibustion,
cupping, herbs, exercises, lifestyle advice)
(i) Lifestyle advices will be given to all participants
(ii) Corticosteroids will be allowed as a rescue medicine of severe pruritus through the
consensus of the KMD in charge of this study and the pharmacist working for Kyung Hee
University Korean Medicine Hospital
(4b) Setting and context of treatment, including instructions to practitioner and information and
explanations to patients
(i) A university hospital
(ii) Participants will be informed about acupuncture treatment in the study as follows: “In this
study, you will be randomly allocated to verum acupuncture treatment or sham acupuncture
treatment and acupoints for AD will be selected based on traditional Korean medicine
textbook and AD-related reports. Also, additional acupoints can be used according to
individual conditions.”
(5) Practitioner background
(5) Description of participating acupuncturists (qualification or professional affiliation, years in
acupuncture practice, other relevant experience)
(i) A KMD who has a license and at least two years of clinical experience in dermatologic
disorders. He attended 10 hours of training and simulation workshop to ensure that he is able
to provide identical acupuncture treatment in accordance with a predefined protocol
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Table 1: Continued.
Item Detail
(6) Control or comparator interventions
(6a) Rationale for the control or comparator in the context of the research question, with sources
that justify this choice
(i) A control group will be treated with sham acupuncture, that is, Park sham acupuncture
needles and nonpenetrating sham PTNs
(6b) Precise description of the control or comparator. If sham acupuncture or any other type of
acupuncture-like control is used, provide details as for items (1) to (3) above
MA: Park sham acupuncture needles and devices will be used in an identical manner as in the
verum acupuncture groups. However, fixed acupuncture treatments will be given to 6 control
points: a point 1 to 2 cm proximal and 1 cm medial to LI7, a point 1 cm proximal and 1 cm
medial to LI11, and a point 1 cm proximal and 1 cm lateral to ST36, each bilaterally
IA: Nonpenetrating sham PTNs, which were designed and validated for blinding for our study,
will be used as a control in an identical manner as in the verum acupuncture groups. The same
sized stainless steel rings without needles, that is, nonpenetrating sham, which were designed
and validated for blinding for our study, will be attached to three control points: a point 1 cm
proximal and 1 cm medial to LI11, bilaterally, and finger point in the ear, contralaterally
AD, atopic dermatitis; IA, intradermal acupuncture; KMD, KoreanMedicine Doctor; MA, manual acupuncture; PTN, press tack needle; STRICTA, STandards
for Reporting Interventions in Clinical Trials of Acupuncture.
Table 2: Study schedule for data collection, treatments, and outcome measures.
Treatment and measures Baseline Treatment period Follow-up period




Visual Analogue Scale for itch I I I I I  I
SCORAD assessment I I I I I I
EASI assessment I I I I I I
POEM assessment I I I I I I
DLQI assessment I I I I I I
TCS evaluation I I I I I  I
AD pattern questionnaire I
Cold-Heat questionnaire e
PPT evaluation I I I
CES-D assessment e I I
STAXI assessment e I I
Credibility test I I I
Acupuncture treatment ⊗ ⊗ ⊗ ⊗
Adverse events ⊗ ⊗ ⊗ ⊗  I
Blood collection e I I
e: conducted on every participant of this study, both AD patients and healthy controls; I: conducted on AD patients of this study, not on healthy controls; ⊗:
conducted on AD patients, but with different frequency on groups. That is, VA1 receives acupuncture treatment or checks adverse events 3 days a week, VA2 2
days a week, and SA 2 days a week; : a telephone interview will be conducted on AD patients of this study, not on healthy controls; AD, atopic dermatitis;
CES-D, Center for Epidemiologic Studies-Depression Scale; Cold-Heat, cold-heat pattern identification based on diagnosis in Traditional Korean Medicine;
DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measure; PPT, Pain Pressure Threshold;
SCORAD, SCORing Atopic Dermatitis; STAXI, state-trait anger expression inventory; TCS, topical corticosteroid.
VA1, and at least 6 sessions of 8 should be completed for VA2
and SA. For dropouts who did not fulfil the aforementioned
compliance criteria, last available data will be taken for the
analysis.
The study coordinator will maintain regular contact and
encourage participants to complete all treatment sessions and
follow-up visits. Should a participant withdraw consent, any
data collected from the participant will be kept in files safely
for 3 years and then will be discarded.
2.10. Outcome Measures. One research nurse who is oth-
erwise not involved in this study will conduct a series
of outcome measures: its schedule is depicted in Table 2.
There will be no separation between primary and secondary
outcomes since it is an exploratory study to evaluate the
independent effectiveness of acupuncture to treat AD and to
collect outcome data for further study.
Participants with AD will complete all the outcome mea-
sures; healthy controls will submit to blood collection and
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complete the Cold-Heat, Centre for Epidemiologic Studies-
Depression Scale (CES-D), and state-trait anger expression
inventory (STAXI) questionnaires.
2.10.1. SCORAD Index. SCORAD is a widely used tool for
assessing severity ofAD.TheSCORADevaluates the intensity
and extent of affected regions and estimates subjective dis-
comfort such as pruritus and sleep loss symptoms [26–28].
The SCORAD index contains 6 items to evaluate AD inten-
sity: erythema, excoriation, oedema or papulation, lichenifi-
cation, oozing or crust, and dryness.The extent of the lesions
is evaluated as a percentage of entire external surface of the
human body with the rule of nine. The SCORAD grades the
intensity and extent of affected skin and the participant rates
their subjective symptoms with VAS (0 = no itch or sleep loss,
to 10 = worst imaginable itch or sleep loss).
2.10.2. Itch VAS. The itchVAS is one of the components of the
SCORAD index, and it will be particularly applied to assess
the severity and reduction of pruritus in this trial. Participants
whose itch VAS score is less than 30 or higher than 80 will be
excluded because we assumed that they will have lower desire
for antipruritic therapy or need more potent treatment [29].
2.10.3. EASI Score. The Eczema Area and Severity Index
(EASI) is a validated instrument measuring AD severity [28,
30]. Questions are specific to four body regions (head and
neck, trunk, upper extremities, and lower extremities) and
four symptoms (erythema, oedema/papulation, excoriation,
and lichenification).
2.10.4. POEM. The Patient Oriented Eczema Measure
(POEM) is a useful, 7-item tool for monitoring AD severity,
which focuses on participant-reported symptoms and illness.
Scores range from 0 to 28, and it is suitable for administration
in the outpatient clinic or in the clinical trial setting [28, 31].
2.10.5. DLQI. TheDermatology Life Quality Index (DLQI) is
a compact questionnaire which is applicable to individuals
with any skin disease. It measures the influence of AD on par-
ticipant’s life over the previous 7 days. It consists of 10 ques-
tions with Likert-type responses and its score ranges from 0
to 30; higher scores imply greater influence on health-related
quality of life [10, 32].
2.10.6. TCS Use. Only Lidomex (prednisolone valeroacetate)
will be permitted as a rescue medicine for severe pruritus, by
consensus of the study KMD and the pharmacist at Kyung
Hee University Korean Medicine Hospital. Participants will
be instructed to apply TCS according to the fingertipmethod:
the ointment will be applied on the surface area of one palm
with amount from the tip of index finger to the distal skin
crease [10].
Participants using TCS will report the amount used,
frequency, and affected regions weekly during this trial. Oint-
mentswill also beweighedweekly before being dispensed and
then again at the end of this study in order to evaluate the
amount of TCS used [33].
2.10.7. AD Pattern Questionnaire. To reflect a unique point of
view on pattern diagnosis in Traditional Korean Medicine in
an objective manner, we adopted the AD pattern question-
naire [34]. Participants with AD will be categorised as either
excess or deficient syndrome by answering 20 “yes or no”
type questions about their AD symptoms and pulse/tongue
diagnoses. A KMD will make diagnoses based on the cate-
gorisation.
2.10.8. Cold-Heat Questionnaire. Identifying cold and heat
pattern is a relatively obvious and definite factor of diagnosis
in Traditional Korean Medicine and the usual cold-heat pat-
tern of patients plays an important role in choosing treatment
modalities and establishing treatment plans [35]. We will use
the questionnaire of cold-heat pattern identification based
on usual conditions and signs. By assessing their usual cold-
heat pattern, participants will be classified into one of four
categories: Cold; Heat; No Cold-Heat; and Cold-Heat com-
plex [36].
2.10.9. PPT. Abdominal examination has been one of the
characteristic methods for diagnosis, choosing a therapy, and
predicting prognosis in Traditional Korean Medicine [37].
We will utilise an algometer to standardise and quantitatively
describe the abdominal examination [38]. Using an algome-
ter (Wagner Instruments, Greenwich, CT), one operator
will apply pressure to 3 acupoints (CV17, CV12, and ST25)
vertically against the surface. Pressure will be applied at a rate
of 1 kg/cm2/sec and participants will be instructed to report
the beginning of pain by saying “stop” immediately after the
perception of pain is transferred frompressure.The examiner
will immediately stop pressing and record the pressure pain
threshold (PPT) value. The maximum PPT will be limited
to 8 kg/cm2 in order to prevent distorted measures. At each
assessment, PPT will be measured three times with the
intervals of 1 minute [38, 39].
2.10.10. CES-D. Since it has been reported that depression is
strongly associated with AD, evaluating depressive symptoms
of the patient is highly recommended [40, 41].TheCES-D is a
reliable tool for nonpsychiatric populations and the validated
Korean version will be used for this trial [42, 43].
2.10.11. STAXI. It is widely reported that AD patients have a
higher risk of depressive symptoms and a reduced capacity
to cope with stress or anger [41, 44]. With a suggested rela-
tionship between depression and anger suppression in AD
patients [41], assessing the anger trait will be valuable to
interpret outcomes in the context of participants’ responses.
STAXI is a validatedmeasure for assessing the experience,
expression, and control of anger. It has 3 subscales such as trait
anger, anger-inside (anger suppression), and anger-outside
(anger expression) and consists of a total of 44 questions [45].
The validated Korean STAXI will be applied for this trial [46].
2.10.12. Credibility Test. To assess the credibility of the
acupuncture treatment used in this study, participants will
complete the credibility questionnaire at baseline, at 4 weeks
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Figure 2: Flow of Illumina sequencing. AD, atopic dermatitis; VA, among VA1 and VA2, the most effective schema will be selected; SA, sham
acupuncture group; wks, weeks. A tube icon means the sera obtained from the blood samples.
(after the termination of treatment period), and at 8 weeks
(after the end of follow-up period) [47, 48].
2.10.13. Measuring Serum Levels of Various Markers. Various
biomarkers have been reported to have different levels in
patients with AD, but none has been validated as a definite
biomarker [49–51]. In this study we will investigate a number
of biomarkers (including IgE) for associations with immuno-
logical, inflammatory, psychological, and endocrine factors
in AD.
About 4ml of whole blood will be collected from par-
ticipants at 3 time points: at baseline; 4 weeks after the
completion of acupuncture treatment; and 8 weeks after the
follow-up period. Healthy controls will submit to only 1 blood
collection (at baseline). Blood will be centrifuged to obtain
serum.
Changes in various biomarker levels from baseline to 4
weeks in each of the treatment groups will be examined.
Between-group differences will be analysed to explore poten-
tial associations with the effect of acupuncture. Analysis of
changes from 4 weeks to 8 weeks in group will be conducted
to evaluate the sustained effect of acupuncture.
(1) SerumTotal IgEMeasurement.The role of IgE in the patho-
genesis of AD is acknowledged as contributing to allergic
sensitisation and indirectly supporting AD severity via sen-
sitisation to various allergens [49]. It has been reported that
anti-IgE therapy has a curative impact on AD and that it
may be an affordable treatment modality [49, 50]. In this
study, total IgE levels will be measured using Enzyme Linked
Immunosorbent Assay (ELISA).
(2) Serum Cytokine/Chemokines Measurement. Based on
knowledge of inflammatory mediators and autoimmune
responses, a diversity of cytokines have been explored in AD
and T cells, and related cytokines are also considered as
potential influencing factors in the pathogenesis of AD [52–
54]. For instance, overexpression of IL-4 and IL-13 in AD skin
was reported and IL-4 was suggested to play a crucial role in
AD development [52, 55, 56].
In this context, we will use a commercial kit (Bio-
Plex Pro Human Chemokine 40-plex Panel) for the
following 40 chemokines from extracted serum samples:
6Ckine/CCL21, BCA-1/CXCL13, CTACK/CCL27, ENA-
78/CXCL5, Eotaxin/CCL11, Eotaxin-2/CCL24, Eotaxin-
3/CCL26, Fractalkine/CX3CL1, GCP-2/CXCL6, GM-CSF,
Gro-𝛼/CXCL1, Gro-𝛽/CXCL2, I-309/CCL1, IFN-𝛾, IL-1𝛽,
IL-2, IL-4, IL-6, IL-8/CXCL8, IL-10, IL-16, IP-10/CXCL10,
I-TAC/CXCL11, MCP-1/CCL2, MCP-2/CCL8, MCP-
3/CCL7, MCP-4/CCL13, MDC/CCL22, MIF, MIG/CXCL9,
MIP-1𝛼/CCL3, MIP-1𝛿/CCL15, MIP-3𝛼/CCL20, MIP-
3𝛽/CCL19,MPIF-1/CCL23, SCYB16/CXCL16, SDF-1𝛼+𝛽/CXCL12,
TARC/CCL17, TECK/CCL25, and TNF-𝛼.
(3) Serum Cortisol Measurement. Cortisol, also called gluco-
corticoid, is a well-known stress-related hormone associated
with the hypothalamic-pituitary-adrenal (HPA) axis and its
mechanisms have been elucidated by analysing physiological
change in stress response systems on a variety of psychologi-
cal issues [57–60]. In this study, serum cortisol level will be
used to assess HPA function in accordance with the stress
response of participants. Total cortisol levels will bemeasured
using ELISA.
2.10.14. Exploring Biomarkers with MicroRNA Expression
Profiling. AD is known as a complex genetic skin disease
affected by environmental distress and resulting from abnor-
mal immune responses as well as malfunctions of the skin
barrier [50, 61]. But no specific biomarker for the diagnosis of
atopic disorder has yet been identified [50, 51]. In this context,
microRNA (miRNA) will be analysed in order to explore new
candidates associated with the development of AD and its
treatment with acupuncture.
A miRNA is a small noncoding RNA molecule. Since its
function is related to eukaryotic cells, dysregulation of several
specific miRNAs has been reported to be associated with
several pathological processes, such as chronic lymphocytic
leukemia and cardiomyopathy [62, 63]. In the study of AD,
some miRNAs were proposed to be related to AD symptoms
[64, 65], but none has been confirmed as a predictive or
prognostic marker.
Illumina sequencing using serum will be performed for
miRNA expression profiling to determine candidate miRNA
biomarkers for the effectiveness of acupuncture. The differ-
ence between participants with AD and healthy controls at
baseline will be analysed to explore potential biomarkers
associated with the development of AD. Within the pool of
biomarker candidates related to AD, the difference between
VA1 or VA2 (whichever is more efficacious) and SA at 4
weeks will be compared, to determine biomarkers related to
acupuncture effect. The difference between VA and SA at 8
weeks will also be analysed to examine whether the selected
biomarkers at 4 weeks continue to be significant at 8 weeks, to
explore sustained effects of acupuncture (Figure 2).
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2.11. Statistical Methods
2.11.1. Sample Size Calculation. The proposed study is a RCT
whose primary aim is to investigate the feasibility to recruit
and treat participants with AD with acupuncture and to
evaluate acupuncture’s antipruritic effects. We will calculate
the effect sizes of key outcomes including itch VAS and
SCORAD index, to inform power calculations for a further
large-scale study. A total of 30 individuals with AD and 20
healthy controls will be recruited during the study period;
participants with AD will be randomly assigned in a 1 : 1 : 1
ratio to one of two active acupuncture regimens or sham
acupuncture. Healthy controls will not receive any treatment.
Considering an estimated 20% dropout rate, we identified the
sample size with the advice of a statistician. The statistical
significance level will be set at 0.1 considering the applied
small size.
2.11.2. Statistical Analysis Plan. We will perform descriptive
analyses for all outcome measures. Categorical variables will
be provided with percentages, and continuous variables will
be provided as means with standard deviations. An indepen-
dent statistician will perform statistical analyses using SPSS
21.0 (IBM SPSS Statistics, New York, USA). Missing data will
be replaced by carrying forward the most recent nonmissing
value, and the time and reason for the missing data will
be recorded. Depending on the recorded reasons, multiple
imputation by an independent statistician will be done and
compared.
The effectiveness of the intervention will be provided by
examining changes in outcome measures between baseline
and end of treatment and through the follow-up period,
using a repeated measures analysis of variance (ANOVA)
and 𝜒2 test. The difference in effect between VA1 and VA2
will be analysed by examining changes in the itch VAS and
SCORAD index, by theMann–Whitney𝑈 test on continuous
variables and 𝜒2 test on categorical variables. The difference
in therapeutic effect between VA (using the most efficacious
dose between VA1 and VA2) and SA will be investigated in
the same way. The data will be analysed with a 𝑝 = 0.1 (two-
sided) statistical significance level and 90% confidence inter-
vals will be provided following the statistician’s advice for a
small sample size. The current data will be used to calculate
the number of participants needed to reach a significance
level of 0.05 and 80% power.
2.12. Protection of Participants
2.12.1. Ethical Approval and Registration. This study protocol
was approved by the ethics committee at Kyung Hee Univer-
sity Korean Medicine Hospital (KOMCIRB-160212-HRBR-
004). It will be performed in accordance with the standards
of the International Committee on Harmonisation on Good
Clinical Practice and the revised version of the Declaration of
Helsinki.This trial was registered viaUSNational Institutes of
Health Clinical Trials registry (ClinicalTrials.gov) on 15 July
2016 (identifier: NCT02844452). The trial registration was
conducted after the start of participant recruitment due to
delays in the preparation of registration.
2.12.2. Participant Safety. During each visit, unanticipated
problems or adverse events related to acupuncture treatment
will be reported by participants and documented by study
staff. Acupuncture treatment has been reported as a safe
treatment rarely causing adverse effects; common adverse
effects caused by acupuncture treatment include bleeding,
hematoma, and pain [66]. Any unfavourable or unexpected
signs related to study treatment or procedures will be com-
piled on paper, managed under the care of practitioners, and
reported to institutional and other oversight agencies as
appropriate.
2.12.3. Quality Control. All participatingKMDs and outcome
assessors will be trained before the beginning of the trial to
ensure consistent quality of practices. The training program
will cover diagnoses, inclusion and exclusion criteria, loca-
tion of the acupoints, acupuncture manipulation techniques,
measurement of PPT, and filling out case report forms. Partic-
ipants who discontinue or who withdraw consent will also be
thoroughly documented.This study will be monitored by the
AMSRC and periodic monitoring will ensure the accuracy
and the quality of this study. We checked Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
to improve the quality of clinical trial protocols (see Addi-
tional File 1 in Supplementary Material available online at
https://doi.org/10.1155/2017/1926806) [67].
2.12.4. Confidentiality. After enrolment, participants’ per-
sonal information will be accessible only to the investigator.
Research data and blood samples will be identified by a
unique code to protect confidentiality during and after the
trial. All study personnel completed training in protection of
personal health information.
2.13. Protocol Amendments. If a protocol modification is
required (such as due to an unanticipated problem or adverse
event), the representatives of Kyung Hee University Korean
Medicine Hospital and the AMSRC will discuss the matter
fully to take the appropriate steps.
3. Discussion
A recent systematic review failed to identify any RCTs
on acupuncture as treatment for AD, as it has not been
extensively researched [15]. We describe a protocol for a
randomised, sham-controlled feasibility trial comparing two
VA groups with different treatment schedules with SA to
assess the effectiveness of acupuncture in individuals with
AD, to be conducted in clinical settings in Korea. The aims
are to evaluate whether the proposed acupuncture treatments
warrant further investigation for improvement of symptoms,
mental health, and quality of life and whether a relationship
can be established between certain biomolecules and the
development of AD by comparing levels in the blood of
individuals with AD to healthy controls.
Determining an optimal dose of acupuncture treatment
involves complex decision making [68, 69]. Clinical practice
and patients’ acceptability should be carefully considered
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when comparing two different dosages/schedules (3 days
weekly versus 2 days weekly for 4 weeks). Our study results
will elucidate which regimen produces maximal effectiveness
and which schedule participants prefer, which is of impor-
tance to practitioners and educators.
We will limit enrolment to individuals with mild to mod-
erate AD. Since KMDs usually treat severe cases with more
intensive combinations of treatment, such as acupuncture
and herbal medicine or acupuncture and hospitalisation, we
selected acupuncture alone in order to detect differences
between treatments without introducing other confounders;
in addition, rescuemedicationwill be permitted as we believe
that this strategy reflects real world practice.
A battery of outcome measures will be used in our
study since it is exploratory in nature. We will investi-
gate the effects of acupuncture treatment on AD symptom
improvement with a particular focus on antipruritic effect,
measured using itch VAS, SCORAD, EASI, and POEM.
Information on rescue medication use and quality of life
will also be collected. For pattern identification in Korean
Medicine, the AD pattern and Cold-Heat questionnaires,
along with PPT, will be administered. CES-D and STAXI
will examine potential anxiolytic and stress-relieving effects
of acupuncture. Through credibility testing, the feasibility of
participant blinding to treatment assignment will be thor-
oughly examined. Some may argue that nonspecific effects
may unnecessarily increase in our trial by the increased
attention due to a variety of outcome measures.The outcome
measures, however, will be given to the participants in all
three groups which will make it unlikely for one specific
group to experience a larger nonspecific benefit due to the
increased attention. We will nevertheless carefully examine
whether there will be additional nonspecific benefits in any
group and the feasible outcome measures will be selected to
work for a main trial. Finally, our study will provide valuable
data regarding treatment of AD with acupuncture, but also
relative to identifying potential biomarkers associatedwith its
development.
Establishing an adequate sham control is essential in an
RCT of acupuncture. We will utilise a nonpenetrating sham
acupuncture and nonpenetrating intradermal needles as a
control group, which receive sham treatment twice a week for
4 weeks.There has been a long debate about the specific effect
of acupuncture: acupuncture works mainly via a placebo
effect [70]; or tested sham acupuncture controls so far may
not be completely inert [71, 72]. The sham control in our
study was designed tominimise a specific physiological effect
that may be induced by needle insertion and to avoid specific
acupuncture points in the body and the ear. In addition, the
number of treatment sessions in the control group was set as
twice weekly to minimise other nonspecific benefits such as
doctor-patient interaction and the Hawthorne effect; this is
feasible due to appropriate blinding techniques.
Attempts have been made to identify biomarkers in
order to measure the specific effects of acupuncture and
to better understand its mechanism of action [73–75], but
no reliable marker has yet to be established due to the
lack of sensitivity and/or specificity. Recently, attention has
increasingly focused on serum circulatingmiRNAs as reliable
noninvasive or minimally invasive biomarkers because they
are abundant, extremely stable in blood, and differentially
expressed in various diseases [76]. Hence, we propose explor-
ing novel miRNA-based candidates in association with the
antipruritic effect of acupuncture, providing new opportuni-




AMSRC: Acupuncture and Meridian Science
Research Center
ANOVA: Analysis of variance
CES-D: Centre for Epidemiologic
Studies-Depression Scale
Cold-Heat: Cold-heat pattern identification based on
diagnosis in Traditional Korean Medicine
EASI: Eczema Area and Severity Index
DLQI: Dermatology Life Quality Index
ELISA: Enzyme Linked Immunosorbent Assay
HPA: Hypothalamic-pituitary-adrenal
IA: Intradermal acupuncture
Itch VAS: Visual Analogue Scale for itch
KMD: Korean Medicine Doctor
MA: Manual acupuncture
miRNA: MicroRNA
POEM: Patient Oriented Eczema Measure
PPT: Pain Pressure Threshold
PTN: Press tack needle
SA: Sham acupuncture group
SCORAD: SCORing Atopic Dermatitis
STAXI: State-trait anger expression inventory
STRICTA: STandards for Reporting Interventions in
Clinical Trials of Acupuncture
TCS: Topical corticosteroid
VA: Verum acupuncture group
VAS: Visual Analogue Scale
VA1: Verum acupuncture group 1
VA2: Verum acupuncture group 2.
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